DFS

EQS-News: Rubean AG quintuples turnover in the first quarter of 2024

Retrieved on: 
Wednesday, April 10, 2024
GPN, EUR, Global Payments, Certification, Discover, Sales management, Growth, WKN, Research, DFS, Fintech, Investment, Diners Club International, Video game

Munich, April 04, 2024: Fintech company Rubean AG, Munich (ISIN: DE0005120802, WKN: 512080, symbol R1B:GR) has continued its strong growth throughout the first quarter of the 2024 financial year.

Key Points: 
  • Munich, April 04, 2024: Fintech company Rubean AG, Munich (ISIN: DE0005120802, WKN: 512080, symbol R1B:GR) has continued its strong growth throughout the first quarter of the 2024 financial year.
  • According to initial calculations, turnover increased by 500% to EUR 493,000 in the first three months of the new year (first quarter of 2023: EUR 98,000).
  • Geopost's Spanish subsidiary, SEUR, has just signed a contract with Rubean to equip thousands of devices with the Rubean solution.
  • Rubean therefore expects revenue to increase by more than 100 percent in 2024 compared to the previous year 2023.

WisdomTree Reports Monthly Metrics for March 2024

Retrieved on: 
Tuesday, April 9, 2024
Professional Services, Technology, Blockchain, Finance, Consulting, Banking, YTD, Commodity, Financial services, AUM, DFS, Cryptocurrency

WisdomTree, Inc. (NYSE: WT), a global financial innovator, today released monthly metrics for March 2024, including assets under management (AUM) and flow data by asset class.

Key Points: 
  • WisdomTree, Inc. (NYSE: WT), a global financial innovator, today released monthly metrics for March 2024, including assets under management (AUM) and flow data by asset class.
  • Higher fee funds drove the over $1.2 billion of net inflows in March and nearly $2 billion of net inflows YTD, generating a positive fee impact
    Generated net inflows in 6 of our 8 major product categories, including double-digit annualized flow growth in Equity, Fixed Income, Commodities and Cryptocurrency
    WisdomTree’s trust company charter granted by the New York State Department of Financial Services (DFS) will enable WisdomTree Prime™ to onboard New York resident customers, and also allows WisdomTree to offer products (like stablecoins) and perform services under DFS supervision with associated legal protections
    Including the forthcoming launch in New York, WisdomTree Prime™ will be available in 41 states and to approximately 75% of the U.S. population

Standard Lithium Installs Commercial DLE Column at Demonstration Plant

Retrieved on: 
Wednesday, March 13, 2024
Lithium, Dorado, FEED, LSS, Boron, Potassium, Arkansas Project, Knowledge, Calcium, FRA, News, Sodium, DFS, Plant, Magnesium, Demonstration, Demonstration plant, DLE, LANXESS, SLI, KTS, Standard

EL DORADO, Ark., March 13, 2024 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, is pleased to announce that it has successfully installed a commercial-scale Direct Lithium Extraction (“DLE”) column at its Demonstration Plant near El Dorado, Arkansas.

Key Points: 
  • EL DORADO, Ark., March 13, 2024 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, is pleased to announce that it has successfully installed a commercial-scale Direct Lithium Extraction (“DLE”) column at its Demonstration Plant near El Dorado, Arkansas.
  • The column has been installed and integrated with the Company’s existing Demonstration Plant to test and derisk the design for commercial applications of the LiPRO™ LSS technology.
  • Standard Lithium’s Director, President & COO, Dr. Andy Robinson commented, “this is an important derisking milestone for Standard Lithium and our partners.
  • With the commercial-scale LSS column, we can continuously test real brine from the Smackover at a commercial level.”
    Figure 1 – Commercial-scale DLE column installed at Standard Lithium’s Demonstration Plant near El Dorado, Arkansas.

Registration Opens For Free Event On Navigating Cancer And Employment, Allsup Explains

Retrieved on: 
Tuesday, March 12, 2024
Diagnosis, Social Security Disability Insurance, Employment, Social Security, HR, Career, SSDI, Health, Partnership, Artificial intelligence, Patient, Knowledge, DFS, TAP, Disability, Disclosure, Social, Survivor, Workforce, Digital divide, Workplace, Nursing, Work, AES, Health insurance

This free virtual event brings together cancer patients, survivors, healthcare professionals, employers and advocates to discuss effective management of treatment, recovery and employment for individuals who have cancer.

Key Points: 
  • This free virtual event brings together cancer patients, survivors, healthcare professionals, employers and advocates to discuss effective management of treatment, recovery and employment for individuals who have cancer.
  • “Cancer and Careers exemplifies genuine commitment to aiding those affected by cancer, whether they’re navigating employment during or after their diagnosis,” said T.J. Geist, Allsup Principal Advocate.
  • AES assigns a dedicated case manager to beneficiaries and offers free support and resources through the Ticket to Work Program.
  • The conference is designed to equip attendees with the knowledge and resources needed to manage their careers through the cancer journey successfully.

Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer

Retrieved on: 
Friday, April 5, 2024
Surgery, Genetics, Clinical Trials, Health Technology, Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Congress, Cystectomy, CDX, Patient, Roche, DNA, DFS, EAU, Bladder cancer, MIBC, NTRA, Survival rate, MRD, FDA, Food, Pharmaceutical industry

The analysis evaluates outcomes in muscle-invasive bladder cancer (MIBC) patients who tested serially negative with Signatera™, Natera’s personalized and tumor-informed molecular residual disease (MRD) test.

Key Points: 
  • The analysis evaluates outcomes in muscle-invasive bladder cancer (MIBC) patients who tested serially negative with Signatera™, Natera’s personalized and tumor-informed molecular residual disease (MRD) test.
  • Sponsored by Genentech, a member of the Roche group, IMvigor011 is a global, double-blind, randomized, Phase III trial, in which high-risk MIBC patients are serially tested with Signatera for up to 12 months post cystectomy.
  • Patients who test Signatera MRD-positive at any point during the 12-month surveillance window are randomized to the anti-PDL1 atezolizumab (Tecentriq®) vs. placebo.
  • “We believe the results of this trial will further demonstrate how Signatera can help personalize treatment decisions and improve outcomes for bladder cancer patients.

Maximus Selected by Florida’s Department of Financial Services to Assist Residents with Outstanding Claims with Insolvent Insurance Companies

Retrieved on: 
Wednesday, April 3, 2024
Other Construction & Property, Construction & Property, Professional Services, Insurance, Partnership, Senior, Financial services, Policy, Florida Department, DFS

Maximus , a leading employer and provider of government services worldwide, today announced the Florida Department of Financial Services (DFS) has selected the company to support residents who have outstanding claims with an insurance company that is no longer operating in the state.

Key Points: 
  • Maximus , a leading employer and provider of government services worldwide, today announced the Florida Department of Financial Services (DFS) has selected the company to support residents who have outstanding claims with an insurance company that is no longer operating in the state.
  • DFS is the appointed receivership for insurance companies that go insolvent or choose to no longer offer coverage in Florida.
  • Our agents will receive information about your new or existing claim and help start the process,” explained Ken Fisher, Senior Managing Director, Maximus.
  • “Maximus has partnered with the state to help manage policy holder requests and we appreciate the trust in Maximus to provide this assistance.

Discover Financial Services Announces First Quarter 2024 Earnings Release On April 17, 2024, and Conference Call on April 18, 2024

Retrieved on: 
Thursday, March 28, 2024
Personal Finance, Payments, Finance, Banking, Professional Services, Technology, Fintech, Digital Cash Management, Digital Assets, Financial services, Central Time, DFS

Discover Financial Services (NYSE: DFS) plans to report its First quarter 2024 results after the market closes on Wednesday, April 17, 2024.

Key Points: 
  • Discover Financial Services (NYSE: DFS) plans to report its First quarter 2024 results after the market closes on Wednesday, April 17, 2024.
  • The earnings release will be available through Discover's Investor Relations website at https://investorrelations.discover.com .
  • A conference call to discuss the firm's results, outlook and related matters will be held on Thursday, April 18, 2024, at 7:00 a.m. Central Time.
  • The live audio webcast will be accessible to the general public through Discover’s Investor Relations website at https://investorrelations.discover.com .

Canada Goose Advances Transformation Program with Organizational Redesign and Leadership Updates

Retrieved on: 
Tuesday, March 26, 2024
Fashion, Online Retail, Retail, Other Retail, Department Stores, Specialty, Growth, DFS, Commercial, Design, GOOS, TSX, Strategy, LVMH, Workforce, Operation, Administration, Management

Today Canada Goose (NYSE, TSX: GOOS) announces a redesign of our global corporate workforce, as part of our ongoing Transformation Program, representing a reduction of approximately 17% of corporate roles.

Key Points: 
  • Today Canada Goose (NYSE, TSX: GOOS) announces a redesign of our global corporate workforce, as part of our ongoing Transformation Program, representing a reduction of approximately 17% of corporate roles.
  • “To those employees who are leaving us, thank you for choosing to spend part of your career at Canada Goose.
  • Daniel Binder, Chief Transformation Officer, will now oversee Global Stores in addition to his current role, which includes Sales Planning & Operations at Canada Goose.
  • Dan has decades of experience in luxury retail, having leadership roles at DFS, a division of LVMH, among other leading luxury retailers and brings strong retail operating skills to this critical growth priority for Canada Goose.

WisdomTree Granted Trust Company Charter by New York State Department of Financial Services (DFS), WisdomTree Prime™ Set to Launch in New York

Retrieved on: 
Friday, March 22, 2024
Technology, Finance, Consulting, Fintech, Banking, Professional Services, Digital Cash Management, Digital Assets, Blockchain, Asset Management, Financial services, Digital asset, DFS, App Store (iOS/iPadOS), Google Play, Ecosystem, Cryptocurrency

The trust company charter authorizes WisdomTree to perform fiduciary custody of digital assets, including digital wallet services, to issue and exchange DFS-approved stablecoins and manage stablecoin reserves under the newly formed entity, WisdomTree Digital Trust Company, LLC.

Key Points: 
  • The trust company charter authorizes WisdomTree to perform fiduciary custody of digital assets, including digital wallet services, to issue and exchange DFS-approved stablecoins and manage stablecoin reserves under the newly formed entity, WisdomTree Digital Trust Company, LLC.
  • “The New York State Department of Financial Services is the premier regulator for businesses that engage in digital asset activity.
  • Specifically, WisdomTree Digital Trust Company will issue the WisdomTree Gold Token and the WisdomTree Dollar Token available in WisdomTree Prime and maintain reserves for those assets under a DFS-approved framework.
  • Additionally, WisdomTree plans to use the WisdomTree Digital Trust Company to offer products and services to institutions and business customers in the future.

Cellworks Personalized Therapy Biosimulation Study Produces Superior OS and DFS Predictions for Gastroesophageal Cancer Patients

Retrieved on: 
Monday, March 11, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Oncology, Research, Software, General Health, Genetics, Health Technology, Science, Data Management, Clinical Trials, Biopsy, OS, HER2, Cancer, Radiation, Kingdom of Poland, Anthracycline, Survival, Disease, Neoadjuvant therapy, CBM, International Cancer Genome Consortium, TNM, University, Patient, Rated R, NGS, Biomarker, MSI, Artificial intelligence, Standard of care, DFS, TRI, MD, Medicine, TRG, Platinum, Publication, Biosimulation, OGA, Whole genome sequencing, PD-L1, Taxane, Medical imaging

The study also showed a significant association between a patient’s TRI score and disease-free survival (DFS) and tumor regression grade (TRG).

Key Points: 
  • The study also showed a significant association between a patient’s TRI score and disease-free survival (DFS) and tumor regression grade (TRG).
  • Despite progress in gastroesophageal cancer therapy, only a small proportion of patients attain long-term survival.
  • This study concluded that TRI scores for gastroesophageal adenocarcinoma patients predict OS and DFS beyond clinical factors.
  • These results highlight the clinical value of employing Cellworks biosimulation for personalized therapy selection and warrant additional clinical evaluation.